Zymeworks (ZYME)
(Delayed Data from NSDQ)
$8.98 USD
-0.14 (-1.54%)
Updated May 20, 2024 04:00 PM ET
After-Market: $8.97 -0.01 (-0.11%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Zymeworks Inc. [ZYME]
Reports for Purchase
Showing records 21 - 40 ( 55 total )
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Board Rejects Takeover Bid; 1Q22 Financials; Modulating PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
2022 Milestones Announced; 25% Workforce Reduction Planned; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
WE THINK THE MARKET IS WRONG THINKING ZYME DOESNOT WORK.
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Zanidatamab Looks to Take on Herceptin in 1L HER2+ GEA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Over the weekend, an abstract highlighting initial phase 2 results for zanidatamab.
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Zanidatamab Phase 2 Gastric Cancer Combo Data at ESMO; Lowering PT to $44
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Partner Program Progress Triggers Milestone Payment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Setting the Bar in 1L HER2+ GEA Cancers; 1Q21 Financials; Lowering PT to $55
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Year-End 2020 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Bursting Onto the Biparatopic Scene; Assuming Coverage at Buy and $57 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Update: Five Active Programs With Zanidatamab, but the Street Awaits Clarity on ZW49
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D